Hennig Arzneimittel &Kg

Executive Summary

Hennig Arzneimittel GmbH & Co. KG is a privately-held, family-owned German pharmaceutical company with over 125 years of heritage, operating since 1946. The company has a dual business model: it develops and markets its own portfolio of generic drugs and over-the-counter (OTC) health products, and it offers contract development and manufacturing organization (CDMO) services for solid dosage forms. Headquartered in Flörsheim am Main, Germany, Hennig serves the domestic and European markets with a focus on high-quality, cost-effective medications. As a mid-sized player, the company benefits from its agility and independence, allowing it to respond quickly to market needs. The generic drugs segment provides a steady revenue stream through established products, while the CDMO segment offers growth opportunities by leveraging its manufacturing expertise for third-party clients. With a strong foundation in the German healthcare system and a reputation for reliability, Hennig is well-positioned to capitalize on the increasing demand for generics and outsourcing in the pharmaceutical industry. However, being private and non-listed limits visibility into its financial performance and strategic plans.

Upcoming Catalysts (preview)

• Q1 2027Launch of new generic drugs in the EU market75% success
• Q4 2026Expansion of CDMO capacity or new client partnerships60% success
• Q3 2026Regulatory approval for an OTC product switch50% success